Secondary CNS myeloma with remission after systemic CNS-penetrating agents.
Neurooncol Adv
; 4(1): vdac106, 2022.
Article
en En
| MEDLINE
| ID: mdl-35892045
ABSTRACT
Background:
CNS myeloma is a rare manifestation of multiple myeloma and is often associated with a dismal prognosis; however, cases are increasing in frequency as overall survival improves for MM. There is currently no standardized treatment for CNS myeloma; however, different chemotherapy and radiotherapy regimens have been described.Methods:
We had previously reported on the efficacy of proton-based craniospinal irradiation in a patient with CNS myeloma; here we present a patient with a history of extramedullary plasmacytoma, 10 years in remission status post standard systemic chemotherapy, with biopsy-proven CNS myeloma successfully treated with systemic chemotherapy as a first-line treatment.Results:
The patient achieved clinical and radiographic remission on 2 separate occasions with systemic chemotherapy alone.Conclusions:
This case demonstrates that systemically administered agents may have activity in CNS myeloma. Further investigations are necessary to establish the optimal combination of agents and treatment schedules.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
Neurooncol Adv
Año:
2022
Tipo del documento:
Article
País de afiliación:
Estados Unidos